fluocortin-butyl-ester and Asthma

The blocking effects of inhaled beclomethasone dipropionate (BDP) and fluocortin butyl ester (FCB) on the immediate and late asthmatic reactions induced by inhaled allergen were studied in two trials. In the first, a double-blind cross-over trial compared BDP (800 micrograms daily as powder) with FCB 8 mg daily (1:20 by wt.-Formulation 1). The second trial was identical in design and compared FCB 8 mg daily (1:20) with FCB 8 mg daily as Formulation 2 (1:40). Known BDP, 400 micrograms daily by pressurized aerosol was studied at the end of the second trial. Allergen provocation was performed before and after 7 days treatment with each drug, with a 2-week interval between each drug. Overall, a blocking index for the immediate reaction of greater than 50% was obtained in ten of twenty patients (50%) using BDP, and five of twenty-one (25%) using FCB (P less than 0.01). The late reaction was blocked in nine of eleven (82%) instances on BDP, and four of fourteen (33%) on FCB. Contrary to earlier reports, inhaled corticosteroid agents used for several days prior to bronchial challenge, were found to block both the immediate as well as the late reaction in many individuals.

Topics: Administration, Intranasal; Allergens; Asthma; Beclomethasone; Bronchial Provocation Tests; Clinical Trials as Topic; Double-Blind Method; Fluocortolone; Forced Expiratory Volume; Humans; Hypersensitivity, Delayed; Hypersensitivity, Immediate

The protective effect of a new inhaled steroid, fluocortin butyl (FCB), was compared to that of disodium cromoglycate (DSCG) and beclomethasone dipropionate (BDP) in patients with extrinsic asthma by means of the allergen-inhalation challenge test. Three different groups of 12 patients each participated in the study. One group was treated with FCB and BDP, the two others with FCB and DSCG, all in a randomized crossover study plan. After an initial allergen challenge (FEV1 fall greater than 15%), the patients were allocated to either treatment for 7-10 days. A second challenge test was then carried out, followed by a washout period of 4 days. The treatments were then crossed-over, and a third allergen challenge was carried out at the end of the second treatment period. With BDP 5 of 12 patients were protected; with FCB, 6 of 12 in two groups and 8 of 12 patients in a third group. With DSCG 3 of 12 patients were protected in the group in which the last medication was given 12 h before challenge, and 8 of 12 patients in the second group in which medication was given 1-2 h before challenge. In the same groups on FCB no such time-dependent effect was observed. No statistically significant differences were found between either FCB and BDP, or FCB and DSCG in either group.

Topics: Allergens; Asthma; Beclomethasone; Cromolyn Sodium; Drug Evaluation; Fluocortolone; Forced Expiratory Volume; Humans; Time Factors

Topics: Adrenal Cortex Hormones; Asthma; Beclomethasone; Cromolyn Sodium; Fluocortolone; Humans; Hypersensitivity, Immediate; Prednisolone

A report was given on a new inhalable corticoid - Fluocortin butylester (FCB) - administered to patients with bronchial asthma. Forty eight cases with extrinsic asthma induced by allergen challenge participated in this study. A good protective effect was seen in 10 patients inhaling 8 mg daily. This dosis produced a remarkable effect of Raw and FRC. No side effects were observed in a study carried over 3 years. Furthermore, there was detected a normal adrenal function during the duration of FCB therapy.

Topics: Aerosols; Asthma; Bronchodilator Agents; Fluocortolone; Humans; Hydrocortisone